• Molecular NameZuclopenthixol
  • SynonymClopenthixol; zuclopenthixol acetate; zuclopenthixol decanoate; zuclopenthixol dihydrochloride; Zuclopenthixolum [latin]; Zuclopentixol [spanish]
  • Weight400.974
  • Drugbank_IDDB01624
  • ACS_NO53772-83-1
  • Show 2D model
  • LogP (experiment)3.9
  • LogP (predicted, AB/LogP v2.0)4.3
  • pka7.6, 3.3
  • LogD (pH=7, predicted)3.51
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.53
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds5
  • TPSA52.01
  • StatusFDA approved
  • AdministrationIntramuscular, oral
  • PharmacologyA typical antipsychotic neuroleptic drug of the thioxanthene group. It mainly acts by antagonism of D1 and D2 dopamine receptors, though it also has some antihistamine activity.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability49.0
  • Protein binding98.0
  • Volume of distribution (VD)15 to 20 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2D6-mediated)
  • Half life20 h (Zuclopenthixol); 1 day (Zuclopenthixol hydrochloride).
  • ExcretionMostly faecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A